PEPTIDE GUARDIANResearch literacy for peptides

Compounds / Mitochondrial and cellular

NAD+

Also written as: Nicotinamide adenine dinucleotide, NAD, Nadide, Coenzyme I, beta-NAD, Diphosphopyridine nucleotide (an older name, used in 1960s papers)

NAD+ is not a peptide but a coenzyme found in every living cell; most human trials tested precursors taken by mouth rather than NAD+ itself, and the evidence for NAD+ by infusion or injection is a handful of small studies with no approved product.

Where the evidence stands

  1. 1 of 4Animal and cell studies only
  2. 2 of 4Early human trials
  3. 3 of 4Late-stage human trials
  4. 4 of 4Approved medicine

The short version

  • NAD+ is not a peptide. It is a coenzyme, a small helper molecule that every living cell uses to turn food into energy. It is not an FDA-approved drug.
  • Most human trials tested NAD+ precursors taken by mouth (nicotinamide riboside or NMN), not NAD+ itself. Those trials raised NAD+ in blood cells but showed mostly modest or no clinical benefit.
  • For NAD+ given into a vein, the published human evidence is small: an 11-man study of blood and urine levels, a 14-person clinic record review, and two single-centre heart trials from one hospital group.
  • A 2026 systematic review found no eligible trial that tested whether infused or injected NAD+ improves ageing or wellness outcomes.
  • The main caution: in the clinic record review all 6 people given NAD+ by vein had moderate to severe symptoms during the infusion, and FDA has received reports of severe chills, shaking and vomiting after compounded NAD+ injections that it said were consistent with bacterial toxins (endotoxins).
  • In the United States NAD+ sits in FDA's Category 1 (under evaluation) for pharmacy compounding. In 2019 FDA proposed leaving it off the list of substances pharmacies may use; that rule has not been finalised.
  • NAD+ is not named on the 2026 or 2027 anti-doping Prohibited List, but the List prohibits large intravenous infusions as a method, whatever is in them.

What it is

NAD+ is not a peptide. Peptides are chains of amino acids. NAD+ (nicotinamide adenine dinucleotide) is a coenzyme: a small helper molecule that enzymes need in order to work. It is present in all living cells. It is often sold alongside peptides, which is why it appears on this site.

More on what it is and where it came from

Chemically it is a dinucleotide. That means two nucleotides (the same kind of building block found in DNA and RNA) joined together through their phosphate groups. One half carries adenine. The other half carries nicotinamide, a form of vitamin B3. Older papers call it diphosphopyridine nucleotide or coenzyme I.

It is not an approved medicine in the United States. The key point for readers is that most human trials people quote did not test NAD+ itself. They tested precursors, the raw materials the body turns into NAD+, taken by mouth: nicotinamide riboside (NR), nicotinamide mononucleotide (NMN) and niacin. Evidence for NAD+ given by infusion (a slow drip into a vein) or by injection is much thinner.

NAD+ was not invented by a company. It is a natural part of cell chemistry. A 2021 review in Nature Reviews Molecular Cell Biology says it was first identified for its role in regulating metabolic rates in yeast extracts and was later shown to be the main carrier of hydrogen in the cell's energy reactions. In 1937 Conrad Elvehjem linked the deficiency disease pellagra to a lack of niacin, a vitamin the body uses to make NAD+. Giving NAD+ itself to patients goes back at least to 1961, when a 'preliminary report' on its use in drug addiction was published under its old name, diphosphopyridine nucleotide. Interest in NAD+ and ageing grew after reports in the early 2000s that NAD+ levels fall with age. Even so, when researchers ran a small infusion study in 2019 they wrote that no data were then available on what happens to directly infused NAD+ in people.

How it is thought to work

Inside cells NAD+ does two jobs. First, it carries electrons in the reactions that turn food into energy, switching back and forth between two forms called NAD+ and NADH. Second, it is used up as a raw material by several enzymes, including sirtuins, PARPs (which help repair DNA) and CD38. Reviews link these enzymes to metabolism, DNA repair and immune cell function.

More on how it works

The body makes NAD+ from the amino acid tryptophan, from niacin (nicotinic acid), and by recycling nicotinamide. NR and NMN feed into the same recycling route. This is why most research gives precursors by mouth. Reviews describe NAD+ itself as not able to pass through the cell membrane, although a transporter that moves whole NAD+ into mitochondria (the cell's power stations) has been reported. In the one small infusion study that tracked blood levels, NAD+ in plasma did not rise for the first two hours, and breakdown products appeared in blood and urine. How much infused NAD+ reaches the inside of human cells intact has not been measured.

The idea behind NAD+ products is that levels fall with age and that topping them up might slow age-related decline. In animal models, restoring NAD+ has slowed or reversed several age-related conditions. The authors of the main review list as open questions how to restore NAD+ safely and whether doing so benefits ageing humans.

What is established in people

Most of what is known in people comes from trials of precursors taken by mouth (nicotinamide riboside and NMN), not NAD+ itself. Those trials show that precursors raise NAD+ in blood cells and are tolerated for weeks to months, but the clinical results are mostly modest or null. For NAD+ given into a vein, the published evidence we found is an 11-man study of blood and urine levels, a 14-person clinic record review, a 1961 preliminary report in addiction that we could not read, and two single-centre trials in hospital heart patients from one research group. No published trial has shown that NAD+ by infusion or injection slows ageing, raises energy, improves thinking or treats addiction, and its long-term safety has not been studied.

What the studies found

11 studies, human trials first. Each links to the paper or registry record.

  1. Human trial2026

    Intravenous infusion of nicotinamide adenine dinucleotide (NAD+) versus nicotinamide riboside (NR): a retrospective tolerability pilot study in a real-world setting

    All 6 people given NAD+ reported moderate to severe symptoms during the infusion: abdominal cramping, diarrhoea, nausea, vomiting, a faster heart rate, throat pain, congestion and chest pressure.

    Full finding, who was studied, and limits

    Who: NAD+ ITSELF, by intravenous infusion, compared with NR by infusion. A look back at the medical records of 14 paying clients of a commercial wellness clinic: 6 had a short course of NAD+ infusions and 8 had NR infusions, with 30 days of follow-up

    All 6 people given NAD+ reported moderate to severe symptoms during the infusion: abdominal cramping, diarrhoea, nausea, vomiting, a faster heart rate, throat pain, congestion and chest pressure. The symptoms stopped when the infusion ended. Clients controlled the drip speed themselves, and NAD+ infusions took 97 minutes on average against 37 minutes for NR. Standard liver, kidney, thyroid and inflammation blood tests did not change significantly. A blood-spot test meant to measure NAD+ could not detect changes.

    Read with care: Not a trial: no randomisation, no placebo, no blinding, 14 people, and it could not show whether NAD+ levels rose. The authors were employed by the clinic chain that gave the infusions and funded the study, and the NR was donated by its maker. The authors list possible bias as a limitation.

    Frontiers in Aging · pubmed.ncbi.nlm.nih.gov

  2. Human trial2026

    Effect of Nicotinamide Adenine Dinucleotide on Heart Failure Caused by Ischemic Cardiomyopathy: A Randomized, Placebo-Controlled Trial

    At one month the heart's pumping measure (ejection fraction) was 45.4% in the NAD+ group and 42.4% in the placebo group (p = 0.024).

    Full finding, who was studied, and limits

    Who: NAD+ ITSELF, by intravenous injection. 180 adults with heart failure after heart muscle damage, at a single hospital in China; randomised to a one-week course of NAD+ or placebo on top of standard treatment

    At one month the heart's pumping measure (ejection fraction) was 45.4% in the NAD+ group and 42.4% in the placebo group (p = 0.024). None of the other outcomes reached statistical significance, including a blood marker of heart strain, symptom class, heart size, and major heart events over six months (14.6% against 24.7%, p = 0.089).

    Read with care: One hospital, a one-week course, and a three-point difference in one scan measure. The abstract does not say whether the trial was blinded and does not report side effects. Patients were seriously ill people in hospital, not healthy adults seeking wellness infusions. Not yet repeated elsewhere.

    American Journal of Cardiovascular Drugs · pubmed.ncbi.nlm.nih.gov

  3. Human trial2026

    Effect of Intravenous Nicotinamide Adenine Dinucleotide on Left Ventricular Function After Primary Percutaneous Coronary Intervention in ST-Segment Elevation Myocardial Infarction: A Randomized Controlled Trial

    At 30 days the ejection fraction was 56.3% in the NAD+ group and 53.4% in the placebo group (p = 0.048).

    Full finding, who was studied, and limits

    Who: NAD+ ITSELF, by intravenous injection. 120 patients who had just had a major heart attack treated by emergency artery opening, at a hospital in China; randomised to a one-week course of NAD+ or placebo on top of standard treatment

    At 30 days the ejection fraction was 56.3% in the NAD+ group and 53.4% in the placebo group (p = 0.048). A blood marker of heart strain was lower with NAD+. Results for changes in heart shape were mixed, and there was no significant difference in major heart events at six months.

    Read with care: Same research group and hospital as the heart failure trial. A small difference that only just reached statistical significance. The abstract does not say whether the trial was blinded and does not report side effects. Heart attack patients in hospital are not comparable to healthy people.

    American Journal of Cardiovascular Drugs · pubmed.ncbi.nlm.nih.gov

  4. Human trial2021

    Nicotinamide mononucleotide increases muscle insulin sensitivity in prediabetic women

    Muscle response to insulin improved by 25% with NMN and did not change with placebo.

    Full finding, who was studied, and limits

    Who: PRECURSOR STUDY (NMN by mouth, not NAD+). 25 postmenopausal women with prediabetes who were overweight or obese (13 on NMN, 12 on placebo); randomised, double-blind, 10 weeks

    Muscle response to insulin improved by 25% with NMN and did not change with placebo. Many other measures did not change: body weight, body fat, liver fat, blood pressure, fasting blood sugar and insulin, the insulin response of liver and fat tissue, the amount of NAD+ in muscle, and muscle strength and fatigue. No side effects were reported.

    Read with care: 25 women, 10 weeks. One laboratory measure improved while the everyday clinical measures did not. Two authors declared patent interests related to NMN. It tested a precursor by mouth, not NAD+ itself.

    Science · pubmed.ncbi.nlm.nih.gov

  5. Human trial2019

    A Pilot Study Investigating Changes in the Human Plasma and Urine NAD+ Metabolome During a 6 Hour Intravenous Infusion of NAD+

    This study measured where infused NAD+ goes, not whether it helps anything.

    Full finding, who was studied, and limits

    Who: NAD+ ITSELF, by intravenous infusion. 11 healthy men aged 30 to 55: 8 received NAD+ over 6 hours and 3 received salt water. Blood and urine were sampled for 8 hours

    This study measured where infused NAD+ goes, not whether it helps anything. NAD+ in blood plasma did not rise for the first two hours. By the end of the infusion it was 398% above the starting level. Breakdown products rose in blood, and both NAD+ and one breakdown product rose in urine (urine NAD+ was up 538% at six hours). No adverse events were recorded. Some liver blood tests shifted slightly; the authors judged the changes not clinically relevant.

    Read with care: Eleven men and a single infusion. No health outcome was measured, and NAD+ inside cells was not measured. The paper does not say whether participants or staff were blinded. The study was run at a clinic that sells NAD+ infusions and was part-funded by a company whose director is the clinic's medical director and a co-author. Eight people is far too few to establish safety.

    Frontiers in Aging Neuroscience · pubmed.ncbi.nlm.nih.gov

  6. Human trial2018

    Chronic nicotinamide riboside supplementation is well-tolerated and elevates NAD+ in healthy middle-aged and older adults

    NAD+ in blood immune cells was about 60% higher on NR than on placebo (unadjusted p = 0.048).

    Full finding, who was studied, and limits

    Who: PRECURSOR STUDY (nicotinamide riboside by mouth, not NAD+). 30 healthy men and postmenopausal women aged 55 to 79 were randomised and 24 completed; double-blind, placebo-controlled crossover, 6 weeks on each

    NAD+ in blood immune cells was about 60% higher on NR than on placebo (unadjusted p = 0.048). No serious side effects occurred. Systolic blood pressure was about 3.9 mmHg lower and a measure of artery stiffness trended lower, but neither result held up after correcting for the number of comparisons. NR had no detectable effect on energy use, body composition, blood sugar or insulin measures, fitness, exercise performance or motor function.

    Read with care: Small and short. The blood pressure and artery findings were exploratory, and the authors said larger trials were needed before any recommendation. The company that sells this form of NR supplied the capsules and part of the funding. This trial tested a precursor taken by mouth and says nothing direct about NAD+ by infusion.

    Nature Communications · pubmed.ncbi.nlm.nih.gov

  7. Human trial2018

    A randomized placebo-controlled clinical trial of nicotinamide riboside in obese men: safety, insulin-sensitivity, and lipid-mobilizing effects

    A null result.

    Full finding, who was studied, and limits

    Who: PRECURSOR STUDY (nicotinamide riboside by mouth, not NAD+). 40 healthy, sedentary men aged 40 to 70 with obesity; investigator-initiated, randomised, double-blind, placebo-controlled, 12 weeks

    A null result. NR did not improve insulin sensitivity, measured with the most rigorous method available (a clamp test). It did not change the body's glucose production or use, resting energy use, fat breakdown or body composition. No serious side effects were attributed to NR.

    Read with care: Men only, 12 weeks, 40 people. It is one of the best-controlled precursor trials and it found no metabolic benefit. It tested a precursor by mouth, not NAD+ itself.

    American Journal of Clinical Nutrition · pubmed.ncbi.nlm.nih.gov

  8. Review2026

    Impact of exogenous nicotinamide adenine dinucleotide and its precursors supplementation in adults with heart failure: a systematic review and meta-analysis of randomized controlled trials

    A result that tempers the single-trial findings.

    Full finding, who was studied, and limits

    Who: A pooled analysis of 4 randomised trials with 387 adults with heart failure, given either intravenous NAD+ or NR by mouth, compared with placebo

    A result that tempers the single-trial findings. Pooled together, NAD+ and NR did not significantly improve hospital admissions for heart failure, deaths, the heart's pumping measure, heart size or a blood marker of heart strain. Blood creatinine, a marker of kidney function, rose by a small but statistically significant amount in the treated groups. The authors called for larger and longer trials.

    Read with care: Only four small trials, and it mixes infused NAD+ with a precursor taken by mouth, so it cannot separate the two. Follow-up was short.

    European Journal of Clinical Pharmacology · pubmed.ncbi.nlm.nih.gov

  9. Review2026

    NAD+ supplementation for anti-aging and wellness: A PRISMA-guided systematic review of preclinical and clinical evidence

    NR and NMN by mouth reliably raised NAD-related markers in human blood and were generally well tolerated over weeks to months.

    Full finding, who was studied, and limits

    Who: A systematic review of 113 studies published from January 2010 to October 2025: 33 in humans (28 randomised, 5 not) and 80 in rodents, covering NAD-related compounds given by mouth or by injection

    NR and NMN by mouth reliably raised NAD-related markers in human blood and were generally well tolerated over weeks to months. But the outcomes that matter to people (function, metabolism, blood vessels) were inconsistent, often showing no effect or an effect on one measure only. No eligible outcome trial tested NAD+ itself by intravenous or intramuscular route. The authors concluded that evidence for anti-ageing or wellness benefit is inconclusive.

    Read with care: The review was limited to ageing and wellness, so trials in specific diseases such as heart failure fall outside it. One author disclosed owning a company that supports an aesthetics clinic, which the disclosure says does not offer NAD+ products.

    Ageing Research Reviews · pubmed.ncbi.nlm.nih.gov

  10. Review2021

    Age-Dependent Decline of NAD+ - Universal Truth or Confounded Consensus?

    The authors concluded that the evidence that NAD+ falls with age is very limited and is often restricted to a single tissue or cell type, and that this is especially true for humans.

    Full finding, who was studied, and limits

    Who: A review of studies that measured NAD+ levels during ageing in yeast, worms, rats, mice, monkeys and humans

    The authors concluded that the evidence that NAD+ falls with age is very limited and is often restricted to a single tissue or cell type, and that this is especially true for humans. They called for larger studies, preferably ones that follow the same people over time, across several tissues.

    Read with care: A narrative review, so it reflects the authors' reading of the literature. It tempers the common statement that NAD+ decline with age is settled fact; it does not show that there is no decline.

    Nutrients · pubmed.ncbi.nlm.nih.gov

  11. Cell study2012

    Age-associated changes in oxidative stress and NAD+ metabolism in human tissue

    NAD+ in skin was lower in older people.

    Full finding, who was studied, and limits

    Who: Skin samples from 49 people aged 15 to 77, plus samples from newborns, taken from the pelvic area during unrelated surgery and measured in the laboratory

    NAD+ in skin was lower in older people. The link with age was moderate to strong in males (r = -0.706, p = 0.001) and weaker in females (r = -0.537, p = 0.01). In males, activity of PARP, an enzyme that uses up NAD+, rose with age.

    Read with care: One tissue (skin), one snapshot per person, 49 people. It shows that NAD+ and age moved together in these samples. It does not show that low NAD+ causes ageing, or that the same happens in other organs. Several of the links were weaker or absent in females.

    PLoS One · pubmed.ncbi.nlm.nih.gov

Safety findings

  • Symptoms during infusion. In a record review at a commercial clinic, all 6 people given NAD+ by vein had moderate to severe symptoms during the infusion: abdominal cramping, diarrhoea, nausea, vomiting, a faster heart rate, throat pain, congestion and chest pressure. The symptoms stopped when the infusion ended. The authors worked for the clinic. Source: pubmed.ncbi.nlm.nih.gov
  • In the 2019 infusion study, no adverse events were recorded in the 8 men who received NAD+ over six hours. Some liver blood tests shifted slightly. Eight people and one infusion cannot establish safety. Source: pubmed.ncbi.nlm.nih.gov
  • FDA reports of reactions to compounded NAD+ injections. An FDA notice (content current as of 30 October 2024) says the agency received adverse event reports after NAD+ injections, with severe chills, shaking, vomiting and fatigue, and that some patients needed medical treatment. FDA said the reactions were consistent with excessive endotoxins (fragments of bacteria that cause fever and shock-like reactions). FDA said it was aware of compounders using food-grade NAD+ sold by repackagers to make intravenous products, and that food-grade ingredients are not suitable for sterile products without appropriate processing. The notice does not give the number of reports. Source: fda.gov
  • An FDA warning letter dated 20 January 2026 to a registered outsourcing facility in Florida describes three patients who developed low blood pressure, uncontrollable shaking, shivers and body aches during or shortly after receiving the firm's NAD+ product from the same vial. All three were sent to the emergency room. The firm had done no finished-product testing before release, and an unopened vial from the same lot was later found to contain excessive bacterial endotoxins (3,360 EU/mL). FDA deemed the product adulterated. Source: fda.gov
5 more safety findings
  • FDA's own assessment of the data. In a 2019 proposed rule, FDA said the animal data it found were inadequate to describe the possible toxicity of NAD, and that it did not find enough clinical data to judge whether NAD is safe in compounded products. FDA also noted that NAD breaks down substantially when exposed to light, moisture, alkaline conditions or ordinary room temperatures. Source: govinfo.gov
  • Kidney marker in heart failure trials. A 2026 pooled analysis of four trials of intravenous NAD+ or NR by mouth in heart failure found a small but statistically significant rise in blood creatinine, a marker of kidney function, in the treated groups. The authors said this needs further evaluation. Source: pubmed.ncbi.nlm.nih.gov
  • Animal safety testing. A 2026 study of NAD+ injected into muscle in dogs, rats, rabbits and guinea pigs reported that at higher amounts dogs had a faster heart rate and lower blood pressure, and that rats given repeated injections had injection-site and nerve changes that reversed after the injections stopped. Tests for muscle irritation, damage to red blood cells and allergic shock were negative. These are animal results, not human safety data. Source: pubmed.ncbi.nlm.nih.gov
  • Long-term effects are unknown. A 2020 benefit and risk review of NAD+ and its precursors noted limited acute toxicity but listed possible risks of raising NAD+ levels: build-up of possibly toxic breakdown products, promotion of tumours, and promotion of cell senescence (cells that stop dividing and release inflammatory signals). These are theoretical concerns drawn largely from laboratory work. A 2026 review of intravenous NAD+ said long-term safety data are lacking and that it should be considered investigational. Source: pubmed.ncbi.nlm.nih.gov
  • Clinics and med spas. FDA's list of compounding risk alerts includes an alert dated 25 October 2021 titled 'FDA highlights concerns with compounding of drug products by medical offices and clinics under insanitary conditions'. A later FDA page (content current as of 30 May 2025) says FDA continues to encourage state nursing, medical and pharmacy boards to work together to address the risks of compounded intravenous hydration solutions used in clinics and med spas. Neither page names NAD+. In August 2026 FDA reported at least 30 patients with adverse events after intravenous glutathione made from a dietary-supplement-grade ingredient, the same kind of ingredient problem it had described for NAD+. Source: fda.gov

Rules and status

Not an FDA-approved drug. NAD+ is on FDA's lists of substances nominated for pharmacy compounding, in Category 1 (under evaluation), which is not an approval. In 2019 FDA proposed not to add it to the list of substances that pharmacies may compound with; that proposal has not been finalised.

The full history, with dates

Approval: there is no FDA-approved NAD+ medicine. On FDA's 503B category list, substances that are components of FDA-approved drugs are marked with two asterisks, and the NAD entry carries none. Compounding by pharmacies (section 503A): FDA's list of nominated bulk drug substances, updated 14 May 2026, places 'Nicotinamide Adenine Dinucleotide (NAD)' in Category 1, 'Bulk Drug Substances Under Evaluation'. FDA explains that Category 1 covers substances that may be eligible for the list of ingredients pharmacies may use, were nominated with enough supporting information, and have not been found to raise significant safety risks; FDA says it does not intend to take action against a compounder using a Category 1 substance provided the conditions in its guidance are met. Category 1 is not approval and is not a finding that the substance is safe or effective. The related substance NADH is also in Category 1, and one salt form ('Beta-Nicotinamide Adenine Dinucleotide Disodium Salt Trihydrate') is in Category 3, which means it was nominated without adequate support. NAD+ does not appear on FDA's page of substances that may present significant safety risks (Category 2 and withdrawn substances; content current 22 April 2026). What FDA has said about the evidence: FDA's Pharmacy Compounding Advisory Committee considered NAD on 8 May 2017 and voted not to include it. On 5 September 2019 FDA published a proposed rule (84 FR 46688) that would not place NAD on the 503A list. The use put forward was fatigue in people with multiple sclerosis. FDA wrote that it identified no published studies supporting NAD for fatigue, that animal and clinical safety data were insufficient, and that NAD is unstable under ordinary storage. The proposed rule states that substances considered and not placed on the list cannot be used in compounding that qualifies for the 503A exemptions. Announced versus in effect: that rule is still a proposal. FDA's 503A page (content current 14 May 2026) says the agency will issue a final regulation after considering comments, and a Federal Register search on 18 November 2026 found no final rule. So NAD remains in Category 1 for now. Outsourcing facilities (section 503B): FDA's 503B category list (dated 21 March 2025, the version on FDA's site on 18 November 2026) places 'Beta-Nicotinamide Adenine Dinucleotide' in 503B Category 1. However, an FDA warning letter of 20 January 2026 to an outsourcing facility stated that NAD+ does not appear on the 503B bulks list and, in a footnote, that it was not eligible for FDA's interim policy for substances under evaluation; the letter does not say which condition was not met. We could not reconcile these two FDA documents and flag this as an open question. FDA stopped sorting new nominations into categories on 7 January 2025. Other 2026 developments: the HHS notice of 30 October 2026 on certain peptides (91 FR 68526) covers peptides only and does not mention NAD+; Appendix A of the policy (on hhs.gov, read from an Internet Archive capture of 15 November 2026) names exactly six peptides, BPC-157, epitalon, KPV, MOTS-c, semax and TB-500, and NAD+ is not among them. Precursors: the regulatory status of NMN as a dietary supplement has been disputed in the United States. We could not open FDA's letters on that question, so it is not covered here.

Source: fda.gov (source dated 2026-05-14)

In sport: Not named on the WADA Prohibited List for 2026 (in force from 1 January 2026) or 2027 (in force from 1 January 2027); neither List, including its index, has an entry for NAD, NAD+, nicotinamide adenine dinucleotide, nicotinamide riboside or NMN. Two general rules on the List are relevant. Class S0 (Non-approved substances) prohibits at all times 'any pharmacological substance which is not addressed by any of the subsequent sections of the List and with no current approval by any governmental regulatory health authority for human therapeutic use'. So S0 applies to NAD+ only if no regulator anywhere has approved it for human therapeutic use. NAD+ is not FDA-approved, but this page did not establish whether any other country's regulator has approved it (injectable 'coenzyme I' products appear in Chinese clinical trials), so whether S0 applies is not settled here. Section M2.2, worded the same in both Lists, prohibits at all times 'intravenous infusions and/or injections of more than a total of 100 mL per 12-hour period except for those legitimately received in the course of hospital treatments, surgical procedures or clinical diagnostic investigations'. This rule is about the method and applies whatever the fluid contains. WADA has not published a ruling on NAD+ that we could find. This is a description of the List, not advice; athletes should check with their anti-doping organisation. WADA

Claims and what the evidence supports

What people sayWhat the evidence supports
NAD+ is a peptide.It is not. Peptides are chains of amino acids. NAD+ is a coenzyme made of two nucleotides, one carrying adenine and one carrying nicotinamide, and PubChem lists it under the names nadide and coenzyme I. It is sold alongside peptides, but it is a different kind of molecule. Source: pubchem.ncbi.nlm.nih.gov
NAD+ infusions are backed by clinical trials.Most of the trials people point to tested precursors taken by mouth (nicotinamide riboside or NMN), not NAD+ by infusion. A 2026 systematic review of ageing and wellness research found no eligible outcome trial of NAD+ itself by intravenous or intramuscular route. Source: pubmed.ncbi.nlm.nih.gov
NAD+ levels fall with age, so topping them up reverses ageing.Lower NAD+ with age has been reported in some human tissues, such as skin samples from 49 people. A 2021 review concluded that the evidence for a general decline is very limited and often restricted to a single tissue, especially in humans. No trial has shown that raising NAD+ reverses ageing in people. Source: pubmed.ncbi.nlm.nih.gov
An infusion delivers NAD+ straight into your cells.In the one small study that tracked it, NAD+ in blood plasma did not rise for the first two hours of the infusion, and breakdown products appeared in blood and urine. NAD+ inside cells was not measured. Reviews describe NAD+ as unable to cross the cell membrane on its own, so how much infused NAD+ reaches the inside of cells intact is not known. Source: pubmed.ncbi.nlm.nih.gov
NAD+ infusions are a proven treatment for addiction and withdrawal.The claim traces back to a 1961 'preliminary report' by one physician, which has no abstract in PubMed, and to a 2019 book by a clinic founder. We found no controlled trial of NAD+ infusion for addiction or withdrawal. Source: pubmed.ncbi.nlm.nih.gov
NAD+ boosters (NR and NMN supplements) are proven to improve metabolism and health.They raise NAD+ in blood cells. Clinical benefits have been modest or absent in the best-controlled trials: 12 weeks of nicotinamide riboside did not improve insulin sensitivity or body composition in 40 men with obesity, and in a trial of 25 women NMN improved muscle insulin response but not weight, blood sugar, blood pressure or liver fat. Source: pubmed.ncbi.nlm.nih.gov
NAD+ is natural to the body, so an infusion has no side effects.In a clinic record review, all 6 people given NAD+ by vein had moderate to severe symptoms during the infusion, including nausea, vomiting, cramping and chest pressure. Separately, FDA has received reports of severe chills, shaking and vomiting after compounded NAD+ injections, which it linked to contamination with endotoxins. Source: fda.gov
NAD+ injections are FDA-approved, or FDA has cleared them as safe.Neither. NAD+ is not an approved drug. It is in FDA's Category 1 for pharmacy compounding, which means under evaluation. In 2019 FDA proposed not to allow it, saying it found no published studies supporting the use put forward and too little safety data. That proposal has not been finalised. Source: govinfo.gov
NAD+ infusions strengthen the heart.Two single-centre trials from one hospital group in China reported a slightly better heart pumping measure one month after a one-week course in hospital heart patients. A pooled analysis of four trials of intravenous NAD+ or NR by mouth in heart failure found no significant benefit for hospital admissions, deaths or heart function. Nothing here applies to healthy people. Source: pubmed.ncbi.nlm.nih.gov

What a genuine lab report should show

  • Identity by mass spectrometry matching the expected molecular weight. PubChem lists NAD+ at 663.4 g/mol (664.4 g/mol for the charged form). A report should also say which form or salt was tested.
  • Purity by HPLC (a method that separates the compound from related impurities), with the chromatogram shown and the percentage stated. For NAD+ this matters more than usual: FDA has noted that it breaks down substantially when exposed to light, moisture, alkaline conditions or ordinary room temperatures, so the test date and the storage conditions should be stated.
  • Bacterial endotoxin and sterility results for any product presented as injectable. The reactions FDA has described after compounded NAD+ injections were consistent with endotoxin contamination, and in one case FDA found a firm had done no finished-product testing before release.
  • The grade of the starting material. FDA has warned that food-grade NAD+ sold by repackagers was used to make intravenous products and is not suitable for that without appropriate processing. A genuine report or certificate should make clear whether the material is pharmaceutical grade.
  • The CAS number 53-84-9, a batch or lot number, the test date and the name of the laboratory, so the report can be traced to the actual material.
  • A lab report describes one batch of a chemical. It is not evidence that the compound is safe or effective in people.

How to read a lab report

What is not known

  • Does NAD+ given by infusion or injection do anything useful in healthy people? No published trial has tested a health outcome outside hospital heart patients.
  • How much infused NAD+ reaches the inside of human cells as NAD+, rather than being broken down first? The one study of blood and urine levels did not measure this.
  • Why do people get symptoms during NAD+ infusions, and does the drip speed explain it? The clinic record review reported symptoms in all 6 people but could not test the cause.
  • Long-term safety of repeated infusions or injections is unstudied. Possible risks raised in reviews (effects on tumours and on cell senescence) are theoretical and untested in people.
  • What did the 1961 addiction report actually find? The PubMed record has no abstract and we could not obtain the paper, so the number of patients and the methods are unknown.
  • FDA's 503B category list (21 March 2025) shows 'Beta-Nicotinamide Adenine Dinucleotide' in Category 1, yet a January 2026 FDA warning letter says NAD+ was not eligible for the interim policy for substances under evaluation. We could not reconcile the two.
  • FDA's 2019 proposal not to place NAD on the 503A list has not been finalised after seven years. If it is finalised as proposed, pharmacies could no longer compound with it under section 503A. This page needs re-checking if a final rule appears.
  • Two studies comparing infused or injected NAD+ with nicotinamide riboside are registered on ClinicalTrials.gov (NCT06382688 and NCT06919328), sponsored by a nutraceutical research institute. No results were posted when we checked on 18 November 2026.
  • A 2026 narrative review describes an uncontrolled pilot of NAD+ infusions in 8 older adults (cited as Braidy, 2018) and a single-patient Parkinson's case report (Rutherford, 2020). We could not find either in PubMed and have not used them.
  • Whether NAD+ falls with age across human tissues is itself disputed. The human data are small, cross-sectional and mostly from single tissues.
  • Whether WADA's class S0 (non-approved substances) applies to NAD+. S0 depends on whether any regulator anywhere has approved it for human therapeutic use. NAD+ is not FDA-approved, but injectable 'coenzyme I' products appear in Chinese clinical trials, and we did not verify its approval status in any country. WADA has not said how it treats NAD+.
  • The dispute over whether NMN can be sold as a dietary supplement in the United States was left out, because we could not open FDA's letters (see researcher notes).

Sources

All 41 sources
  1. PubChem: Nadide (NAD), CID 5892 - formula, molecular weight, CAS number, synonyms. pubchem.ncbi.nlm.nih.gov
  2. PubChem: NAD+ (charged form), CID 5893. pubchem.ncbi.nlm.nih.gov
  3. Covarrubias et al. 2021, NAD+ metabolism and its roles in cellular processes during ageing (Nat Rev Mol Cell Biol). pubmed.ncbi.nlm.nih.gov
  4. Covarrubias et al. 2021, author manuscript on PMC (history, pathways, cell entry, risks). pmc.ncbi.nlm.nih.gov
  5. Braidy and Liu 2020, NAD+ therapy in age-related degenerative disorders: a benefit/risk analysis (Exp Gerontol). pubmed.ncbi.nlm.nih.gov
  6. Massudi et al. 2012, NAD+ and age in human skin samples (PLoS One). pubmed.ncbi.nlm.nih.gov
  7. Zhu et al. 2015, brain NAD+ and age by magnetic resonance in 17 volunteers (PNAS). pubmed.ncbi.nlm.nih.gov
  8. Peluso et al. 2021, Age-Dependent Decline of NAD+ - Universal Truth or Confounded Consensus? (Nutrients). pubmed.ncbi.nlm.nih.gov
  9. Martens et al. 2018, nicotinamide riboside crossover trial in older adults (Nat Commun) - precursor. pubmed.ncbi.nlm.nih.gov
  10. Dollerup et al. 2018, nicotinamide riboside in men with obesity (Am J Clin Nutr) - precursor. pubmed.ncbi.nlm.nih.gov
  11. Yoshino et al. 2021, NMN in prediabetic women (Science) - precursor. pubmed.ncbi.nlm.nih.gov
  12. Grant et al. 2019, six-hour intravenous NAD+ infusion pilot (Front Aging Neurosci). pubmed.ncbi.nlm.nih.gov
  13. Reyna et al. 2026, intravenous NAD+ versus NR, retrospective clinic record review (Front Aging). pubmed.ncbi.nlm.nih.gov
  14. O'Hollaren 1961, diphosphopyridine nucleotide in drug addiction, preliminary report (West J Surg Obstet Gynecol) - no abstract. pubmed.ncbi.nlm.nih.gov
  15. Yu et al. 2026, intravenous NAD+ in heart failure from ischemic cardiomyopathy, randomised trial (Am J Cardiovasc Drugs). pubmed.ncbi.nlm.nih.gov
  16. Yu et al. 2026, intravenous NAD+ after heart attack, randomised trial (Am J Cardiovasc Drugs). pubmed.ncbi.nlm.nih.gov
  17. Hamzah et al. 2026, NAD+ and precursors in heart failure, meta-analysis of four trials (Eur J Clin Pharmacol). pubmed.ncbi.nlm.nih.gov
  18. Gallagher and Emmanuel 2026, systematic review of NAD+ supplementation for anti-ageing and wellness (Ageing Res Rev). pubmed.ncbi.nlm.nih.gov
  19. Alangari et al. 2026, narrative review of intravenous NAD+ and precursors (Front Aging). pubmed.ncbi.nlm.nih.gov
  20. Gindri et al. 2024, systematic review of randomised trials of NADH and NAD precursors, 10 studies, 489 participants (Am J Physiol Endocrinol Metab). pubmed.ncbi.nlm.nih.gov
  21. Radenkovic, Reason and Verdin 2020, Clinical Evidence for Targeting NAD Therapeutically (Pharmaceuticals). pubmed.ncbi.nlm.nih.gov
  22. Gu et al. 2026, animal safety testing of injected NAD+ (Biomed Pharmacother). pubmed.ncbi.nlm.nih.gov
  23. ClinicalTrials.gov NCT06382688, IV Niagen vs NAD+ (no results posted on 18 November 2026). clinicaltrials.gov
  24. ClinicalTrials.gov NCT06919328, injectable Niagen+ vs NAD+ (recruiting; no results posted on 18 November 2026). clinicaltrials.gov
  25. FDA: Bulk Drug Substances Nominated for Use in Compounding Under Section 503A (category list, updated 14 May 2026). fda.gov
  26. FDA: Bulk Drug Substances Used in Compounding Under Section 503A (category definitions; content current 14 May 2026). fda.gov
  27. FDA: Bulk Drug Substances Nominated for Use in Compounding Under Section 503B (category list, updated 21 March 2025). fda.gov
  28. FDA: Bulk Drug Substances Used in Compounding Under Section 503B (content current 7 January 2025). fda.gov
  29. Federal Register, 5 September 2019: proposed rule on the 503A bulk drug substances list, including FDA's evaluation of NAD (84 FR 46688). govinfo.gov
  30. Federal Register, 17 April 2017: notice of the Pharmacy Compounding Advisory Committee meeting that considered NAD. federalregister.gov
  31. FDA: Certain Bulk Drug Substances for Use in Compounding that May Present Significant Safety Risks (content current 22 April 2026; NAD+ not listed). fda.gov
  32. FDA reminds compounders to use ingredients suitable for sterile compounding (NAD+ injection adverse events; content current 30 October 2024). fda.gov
  33. FDA warning letter to GenoGenix LLC, 20 January 2026 (NAD+ product, three patients, endotoxin). fda.gov
  34. FDA: Compounding Risk Alerts (list of alerts, including 25 October 2021 alert on medical offices and clinics; content current 27 August 2026). fda.gov
  35. FDA responses to action items from the 2023 intergovernmental meeting on drug compounding (IV hydration in clinics and med spas; content current 30 May 2025). fda.gov
  36. FDA reminds compounders not to use dietary supplement grade glutathione for injectables (27 August 2026). fda.gov
  37. Federal Register, 30 October 2026: HHS enforcement discretion policy on certain peptide bulk drug substances (91 FR 68526; does not mention NAD+). govinfo.gov
  38. WADA Prohibited List (official page). wada-ama.org
  39. WADA 2026 Prohibited List (sections S0 and M2.2 and the index). wada-ama.org
  40. WADA 2027 Prohibited List, published 21 September 2026, in force 1 January 2027. wada-ama.org
  41. HHS Enforcement Discretion Policy Regarding 503A Compounding Using Certain Peptide Bulk Drug Substances, with Appendix A (the six peptides) and Appendix B (HHS reasoning); read from an Internet Archive capture of 15 November 2026. hhs.gov

Sources last checked 2026-11-18.

This page summarises published research and public records for education. It is not medical advice and it is not a guide to using any compound. If something here is wrong or out of date, tell us and we will correct it.

Get the Guardian Field Guide

Every compound on this site in one guide: what it is, what studies found, and where it stands with regulators. Sent to your email, with a note when a compound page or its legal status changes.

Sign-up link not connected yet.